Children's Oncology Group's 2023 Blueprint for Research: Cellular Therapy and Stem Cell Transplantation

Authors

Carrie L. Kitko, Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Catherine M. Bollard, Center for Cancer and Immunology Research, Children's National Hospital, Washington, District of Columbia, USA.
Mitchell S. Cairo, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Maria Fareri Children's Hospital, Westchester Medical Center, New York Medical College, Valhalla, New York, USA.Follow
Joseph Chewning, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Terry J. Fry, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Michael A. Pulsipher, Division of Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine, Salt Lake City, Utah, USA.
Shalini Shenoy, Division of Pediatric Hematology and Oncology, Department of Pediatrics, Washington University, St Louis, Missouri, USA.
Donna A. Wall, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada.
John E. Levine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Author Type(s)

Faculty

DOI

10.1002/pbc.30577

Journal Title

Pediatric Blood & Cancer

First Page

e30577

Document Type

Article

Publication Date

9-1-2023

Department

Pediatrics

Abstract

Since the publication of the last Cellular Therapy and Stem Cell Transplant blueprint in 2013, Children's Oncology Group cellular therapy-based trials advanced the field and created new standards of care across a wide spectrum of pediatric cancer diagnoses. Key findings include that tandem autologous transplant improved survival for patients with neuroblastoma and atypical teratoid/rhabdoid brain tumors, one umbilical cord blood (UCB) donor was safer than two UCB donors, killer immunoglobulin receptor (KIR) mismatched donors did not improve survival for pediatric acute myeloid leukemia when in vivo T-cell depletion is used, and the depth of remission as measured by next-generation sequencing-based minimal residual disease assessment pretransplant was the best predictor of relapse for acute lymphoblastic leukemia. Plans for the next decade include optimizing donor selection for transplants for acute leukemia/myelodysplastic syndrome, using novel engineered cellular therapies to target a wide array of malignancies, and developing better treatments for cellular therapy toxicities such as viral infections and graft-vs-host disease.

Recommended Citation

Kitko, C. L., Bollard, C. M., Cairo, M. S., Chewning, J., Fry, T. J., Pulsipher, M. A., Shenoy, S., Wall, D. A., & Levine, J. E. (2023). Children's Oncology Group's 2023 Blueprint for Research: Cellular Therapy and Stem Cell Transplantation. Pediatric Blood & Cancer, 70 Suppl 6 (Suppl 6), e30577. https://doi.org/10.1002/pbc.30577